Arix Bioscience Leads $65M Funding Round For Iterum
By Benjamin Horney · May 19, 2017, 1:28 PM EDT
A recently established unit of health care and life science company Arix Group that is focused on the development of an oral and intravenous antibiotic to treat Gram-negative multi-drug resistant infections...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login